43 related articles for article (PubMed ID: 21245486)
1. NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II{alpha} and DNA-dependent protein kinase.
Hisatomi T; Sueoka-Aragane N; Sato A; Tomimasu R; Ide M; Kurimasa A; Okamoto K; Kimura S; Sueoka E
Blood; 2011 Mar; 117(13):3575-84. PubMed ID: 21245486
[TBL] [Abstract][Full Text] [Related]
2. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K.
Munck JM; Batey MA; Zhao Y; Jenkins H; Richardson CJ; Cano C; Tavecchio M; Barbeau J; Bardos J; Cornell L; Griffin RJ; Menear K; Slade A; Thommes P; Martin NM; Newell DR; Smith GC; Curtin NJ
Mol Cancer Ther; 2012 Aug; 11(8):1789-98. PubMed ID: 22576130
[TBL] [Abstract][Full Text] [Related]
4. The Novel C-terminal Truncated 90-kDa Isoform of Topoisomerase II
Kanagasabai R; Karmahapatra S; Kientz CA; Yu Y; Hernandez VA; Kania EE; Yalowich JC; Elton TS
Mol Pharmacol; 2018 May; 93(5):515-525. PubMed ID: 29514855
[TBL] [Abstract][Full Text] [Related]
5. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination.
Tavecchio M; Munck JM; Cano C; Newell DR; Curtin NJ
Cancer Chemother Pharmacol; 2012 Jan; 69(1):155-64. PubMed ID: 21630086
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of topoisomerase IIA (Top2α) induces telomeric DNA damage and T cell dysfunction during chronic viral infection.
Dang X; Ogbu SC; Zhao J; Nguyen LNT; Cao D; Nguyen LN; Khanal S; Schank M; Thakuri BKC; Wu XY; Morrison ZD; Zhang J; Li Z; El Gazzar M; Ning S; Wang L; Wang Z; Moorman JP; Yao ZQ
Cell Death Dis; 2020 Mar; 11(3):196. PubMed ID: 32193368
[TBL] [Abstract][Full Text] [Related]
7. DNA-PKcs kinase activity stabilizes the transcription factor Egr1 in activated immune cells.
Waldrip ZJ; Burdine L; Harrison DK; Azevedo-Pouly AC; Storey AJ; Moffett OG; Mackintosh SG; Burdine MS
J Biol Chem; 2021 Oct; 297(4):101209. PubMed ID: 34562454
[TBL] [Abstract][Full Text] [Related]
8. Cadmium-coordinated supramolecule suppresses tumor growth of T-cell leukemia in mice.
Zhou X; Koizumi Y; Zhang M; Natsui M; Koyota S; Yamada M; Kondo Y; Hamada F; Sugiyama T
Cancer Sci; 2015 May; 106(5):635-41. PubMed ID: 25735932
[TBL] [Abstract][Full Text] [Related]
9. Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.
Willoughby CE; Jiang Y; Thomas HD; Willmore E; Kyle S; Wittner A; Phillips N; Zhao Y; Tudhope SJ; Prendergast L; Junge G; Lourenco LM; Finlay MRV; Turner P; Munck JM; Griffin RJ; Rennison T; Pickles J; Cano C; Newell DR; Reeves HL; Ryan AJ; Wedge SR
J Clin Invest; 2020 Jan; 130(1):258-271. PubMed ID: 31581151
[TBL] [Abstract][Full Text] [Related]
10. Selective DNA-PK Inhibition Enhances Chemotherapy and Ionizing Radiation Activity in Soft-Tissue Sarcomas.
Laroche-Clary A; Josensi C; Derieppe MA; Belhomme S; Vendrely V; Perret R; Cadogan E; Italiano A
Clin Cancer Res; 2024 Feb; 30(3):629-637. PubMed ID: 37982819
[TBL] [Abstract][Full Text] [Related]
11.
Wang X; Carvajal-Moreno J; Zhao X; Li J; Hernandez VA; Yalowich JC; Elton TS
Mol Pharmacol; 2024 May; ():. PubMed ID: 38719474
[TBL] [Abstract][Full Text] [Related]
12. Human T cell leukemia cell death by apoptosis-inducing nucleosides from CD57(+) HLA-DR(bright) natural suppressor cell line.
Mori T; Li X; Mori E; Guo M
Jpn J Cancer Res; 2000 Jun; 91(6):629-37. PubMed ID: 10874216
[TBL] [Abstract][Full Text] [Related]
13. Targeting the DNA damage response in hematological malignancies.
De Mel S; Lee AR; Tan JHI; Tan RZY; Poon LM; Chan E; Lee J; Chee YL; Lakshminarasappa SR; Jaynes PW; Jeyasekharan AD
Front Oncol; 2024; 14():1307839. PubMed ID: 38347838
[TBL] [Abstract][Full Text] [Related]
14. Exploration of the Role of the C-Terminal Domain of Human DNA Topoisomerase IIα in Catalytic Activity.
Dougherty AC; Hawaz MG; Hoang KG; Trac J; Keck JM; Ayes C; Deweese JE
ACS Omega; 2021 Oct; 6(40):25892-25903. PubMed ID: 34660952
[TBL] [Abstract][Full Text] [Related]
15. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.
Ma Y; North BJ; Shu J
Mol Biol Rep; 2021 Sep; 48(9):6589-6601. PubMed ID: 34476738
[TBL] [Abstract][Full Text] [Related]
16. Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives.
Marinello J; Delcuratolo M; Capranico G
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404148
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, Bacteriostatic and Anticancer Activity of Novel Phenanthridines Structurally Similar to Benzo[c]phenanthridine Alkaloids.
Lasák P; Motyka K; Kryštof V; Stýskala J
Molecules; 2018 Aug; 23(9):. PubMed ID: 30150591
[TBL] [Abstract][Full Text] [Related]
18. A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.
Bisacchi GS; Hale MR
Curr Med Chem; 2016; 23(6):520-77. PubMed ID: 26695512
[TBL] [Abstract][Full Text] [Related]
19. From Immunodeficiency to Humanization: The Contribution of Mouse Models to Explore HTLV-1 Leukemogenesis.
Pérès E; Bagdassarian E; This S; Villaudy J; Rigal D; Gazzolo L; Duc Dodon M
Viruses; 2015 Dec; 7(12):6371-86. PubMed ID: 26690200
[TBL] [Abstract][Full Text] [Related]
20. DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer.
Velic D; Couturier AM; Ferreira MT; Rodrigue A; Poirier GG; Fleury F; Masson JY
Biomolecules; 2015 Nov; 5(4):3204-59. PubMed ID: 26610585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
